每周一次替尔泊肽与每日一次德谷胰岛素对2型糖尿病成人血糖控制的疗效比较(基于连续血糖监测的SURPASS-3 CGM子研究):随机、开放标签、平行分组、3期SURPASS-3试验的子研究
SURPASS-3 CGM子研究在2型糖尿病成人中比较每周一次替尔泊肽与每日一次德谷胰岛素对连续血糖监测指标的影响。52周时,替尔泊肽10 mg和15 mg合并组血糖在严格目标范围(71-140 mg/dL)内的时间比例较德谷胰岛素组高25%(95%CI 16-33;p<0.0001)。替尔泊肽5 mg、10 mg、15 mg组52周时严格目标范围内时间均显著多于德谷胰岛素组。
要点
- 52周时替尔泊肽10 mg和15 mg合并组严格目标范围内时间较德谷胰岛素组高25%(95%CI 16-33;p<0.0001)。
- 52周时替尔泊肽5 mg、10 mg、15 mg组严格目标范围内时间分别较德谷胰岛素组高12%、24%、25%。
- 24周时替尔泊肽10 mg和15 mg组严格目标范围内时间显著多于德谷胰岛素组,5 mg组无显著差异。
核心结论
- 在二甲双胍(联用或不联用SGLT2抑制剂)治疗的2型糖尿病参与者中,每周一次替尔泊肽经连续血糖监测评估的血糖控制优于德谷胰岛素。
- 这些新数据为替尔泊肽的效应提供了额外证据,并提示与基础胰岛素相比在不增加低血糖风险的情况下实现血糖目标的潜力。
研究设计与样本
- 本研究的SURPASS-3 CGM子研究为开放标签、平行分组、3期SURPASS-3试验的子研究,在六个国家(匈牙利、波兰、罗马尼亚、西班牙、乌克兰和美国)的45个中心进行。
- 主研究纳入接受二甲双胍单药或联合SGLT2抑制剂至少3个月、胰岛素未治、基线HbA1c 7.0-10.5%(53-91 mmol/mol)、BMI≥25 kg/m2的2型糖尿病成人,按1:1:1:1随机分配至每周一次皮下注射替尔泊肽5 mg、10 mg或15 mg,或每日一次皮下注射滴定德谷胰岛素(100 U/mL)。
- 子研究纳入 wake-sleep 周期正常的部分患者,在基线、24周和52周通过连续血糖监测收集约7天的组织间液葡萄糖值。
- 主要结局在所有随机分配、至少接受一剂研究药物且在基线或基线后至少有一次可评估连续血糖监测的参与者中评估,比较替尔泊肽10 mg和15 mg合并组与德谷胰岛素组52周时连续血糖监测值处于严格目标范围(71-140 mg/dL)的时间比例。
- 2019年4月1日至11月27日筛查313人,243人纳入CGM子研究(替尔泊肽5 mg n=64;10 mg n=51;15 mg n=73;德谷胰岛素 n=55)。
主要发现
- 52周时替尔泊肽10 mg和15 mg合并组严格目标范围内时间比例较德谷胰岛素组高25%(95%CI 16-33;p<0.0001)。
- 52周时替尔泊肽5 mg组严格目标范围内时间较德谷胰岛素组高12%(95%CI 1-22;p=0.031),10 mg组高24%(95%CI 13-35;p<0.0001),15 mg组高25%(95%CI 14-35;p<0.0001)。
- 24周时替尔泊肽10 mg组严格目标范围内时间较德谷胰岛素组高19%(95%CI 8-30;p=0.0008),15 mg组高21%(95%CI 11-31;p<0.0001),5 mg组无显著差异。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Tirzepatide is a novel dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist under development for the treatment of type 2 diabetes. In this study, we used continuous glucose monitoring (CGM) to compare the 24 h glucose profile for participants given tirzepatide compared with those given insulin degludec. METHODS: This substudy of the open-label, parallel-group, phase 3 SURPASS-3 trial, was done at 45 sites across six countries (Hungary, Poland, Romania, Spain, Ukraine, and the USA). Eligible participants in the main study were adults with type 2 diabetes, a baseline HbA1c of 7·0-10·5% (53-91 mmol/mol), and a BMI of 25 kg/m2 or more, who were insulin-naive, and treated with metformin alone or in combination with a SGLT2 inhibitor for at least 3 months before screening. Participants in the main study were randomly assigned (1:1:1:1) to receive once-weekly subcutaneous injection of tirzepatide 5 mg, 10 mg, or 15 mg, or once-daily subcutaneous injection of titrated insulin degludec (100 U/mL), using an interactive web-response system. Participants were stratified by country, HbA1c concentration, and concomitant oral antihyperglycaemic medication. A subset of these patients with a normal wake-sleep cycle were enrolled into this substudy, and interstitial glucose values were collected by CGM for approximately 7 days at baseline, 24 weeks, and 52 weeks. The primary outcome was to compare pooled participants assigned to 10 mg and 15 mg tirzepatide versus insulin degludec for the proportion of time that CGM values were in the tight target range (71-140 mg/dL) at 52 weeks, assessed in all randomly assigned participants who received at least one dose of study drug and had an evaluable CGM session at either baseline or after baseline. The secondary outcomes were to compare tirzepatide (5 mg, 10 mg, and 15 mg) versus insulin degludec for the proportion and duration of time in tight target range at 24 and 52 weeks. This was a substudy of the trial registered with ClinicalTrials.gov, NCT03882970, and is complete. FINDINGS: From April 1 to Nov 27, 2019, 313 participants were screened for eligibility, 243 of whom were enrolled in CGM substudy (tirzepatide 5 mg, n=64; tirzepatide 10 mg, n=51; tirzepatide 15 mg, n=73; and insulin degludec, n=55). Patients given once-weekly tirzepatide (pooled 10 mg and 15 mg groups) had a greater proportion of time in tight target range compared with patients given insulin degludec (estimated treatment difference 25% [95% CI 16-33]; p<0·0001). Participants assigned to tirzepatide spent significantly more time in tight target range at 52 weeks compared with those assigned to insulin degludec (5 mg 12% [1-22], p=0·031; 10 mg 24% [13-35], p<0·0001; and 15 mg 25% [14-35], p<0·0001). Participants assigned to tirzepatide 10 mg and 15 mg, but not to tirzepatide 5 mg, spent significantly more time in tight target range at 24 weeks compared with insulin degludec (10 mg 19% [8-30], p=0·0008; 15 mg 21% [11-31], p<0·0001). INTERPRETATION: Once-weekly treatment with tirzepatide showed superior glycaemic control measured using CGM compared with insulin degludec in participants with type 2 diabetes on metformin, with or without a SGLT2 inhibitor. These new data provide additional evidence to the effect of tirzepatide and potential for achieving glycaemic targets without increase of hypoglycaemic risk compared with a basal insulin. FUNDING: Eli Lilly and Company.
引用
- Battelino T, Bergenstal RM, Rodríguez A, et al. Efficacy of once-weekly tirzepatide versus once-daily insulin degludec on glycaemic control measured by continuous glucose monitoring in adults with type 2 diabetes (SURPASS-3 CGM): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial. Lancet Diabetes Endocrinol. 2022. PMID: 35468321. doi:10.1016/S2213-8587(22)00077-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。